The race to expand the market share of ‘new lipid formulation total parenteral nutrition’ has been ignited by pharmaceutical companies specializing in parenteral nutrition.

The new intravenous lipid total parenteral nutritions that have been introduced to the market are regarded as 4th generation total parenteral nutritions and are an amino acid admixture to the existing three-chamber bags for parenteral nutrition.

It consists of refined fish oil (Omega-3) or refined olive oil, amino acids, and glucose.

Baxter was the first company to enter the market with a 4th generation product, which received authorization in August last year.

Baxter’s Olimer N12E In